How to Cite
Abstract
The outcomes of multimodality treatment of 227 glioblastoma (grade IV) patients were evaluated in relation to the postoperative chemoradiotherapy (ChRT) regimen. No statistically significant differences were found in groups with conventional ChRT (temozolomide 75 mg/m2 per os 1 hour before the radiation treatment during the whole course of radiotherapy, n=111) and modified ChRT (temozolomide 75 mg/m2 per os 5 days a week 1 hour before the radiation treatment in the first and last two weeks of radiotherapy, n=116), the median overall survival being 16 months and 16 months respectively (P=0,889). The Cox proportional hazards model demonstrated that the postoperative ChRT regimen was not a prognostic factor affecting patient survival.References
Синайко В.В., жаврид Э.А., Артемова н.А. Модифицированная химиолучевая терапия при высокозлокачественных глиальных опухолях головного мозга // Здравоохранение. - 2015. - № 12. - С. 49-54.
Синайко В.В., Жаврид Э.А., Демешко П.Д., Артемова H.А. Отдаленные результаты комплексного лечения пациентов с глиобластомой (Grade IV): суммарные дозы темозоломида и факторы прогноза // Евразийский онкологический журнал. - 2016. - Т. 4. - № 3. - С. 669-677.
Armstrong T.S., Wefel J.S., Wang M. et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma // J. Clin. Oncol. - 2013. - Vol. 31. - № 32. - P. 4076-4084.
Gilbert M.R., Wang M., Aldape K.D. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial // J. Clin. Oncol. - 2013. - Vol. 31. - № 32. - P. 4085-4091.
Hottinger A.F., Stupp R., Homicsko K. Standards of care and novel approaches in the management of glioblastoma multiforme // Chin. J. Cancer. - 2014. - Vol. 33. - № 1. - Р. 32-39.
Ostrom Q.T., Gittleman H., Farah P et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010 // Neuro Oncol. - 2013. - Vol. 15 (Suppl. 2). - P. ii1-ii6.
Stupp R., Hegi M.E., Mason W.P. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial // Lancet Oncol. - 2009. - Vol. 10. - № 5. - P. 459-466.
Villà S., Balana C., Comas S. Radiation and concomitant chemotherapy for patients affected with glioblastoma multiforme // Chin. J. Cancer. - 2014. - Vol. 33. - № 1. - Р. 25-31.
Yabroff K.R., Harlan L., Zeruto C., Abrams J. et al. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006 // Neuro Oncol. - 2012. - Vol. 14. - № 3. - Р. 351-359.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017